Shenyang Chemical Industry (000698.SZ) announces an expected net loss of 168 million to 231 million yuan for the year 2024.
Shenyang Chemical Industry (000698.SZ) released its 2024 annual performance forecast, expecting the full year net profit attributable to shareholders of the listed company to...
Shenyang Chemical Industry (000698.SZ) has announced its performance forecast for the year 2024, expecting a net loss attributable to the shareholders of the listed company in the range of 168 million yuan to 231 million yuan, a decrease of 49.59% to 63.34% compared to the previous year.
During the reporting period, the company's subsidiary Shenyang Paraffin Chemical Co., Ltd. entered bankruptcy proceedings, causing the company to lose control over it and therefore it is no longer included in the consolidated financial statements. The overall performance of the listed company decreased compared to the previous year. Following a prudent approach, the parent company made provisions for credit impairment losses, resulting in a decrease in the total profit of the parent company compared to the previous year. In terms of production and operation, the company and its subsidiary Sinochem East China (Zibo) Co., Ltd. optimized their personnel structure, deeply explored cost reduction potential, and implemented a series of management measures to improve the company's performance.
Related Articles

WEIMOB INC (02013) plans to discount approximately 8.87% of the total issued shares of 6.88 billion subscription shares, raising approximately 1.55 billion HKD.

ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.

DL Holdings GP (01709): Purchased 2.152 million shares under the restricted stock incentive plan for the year 2025.
WEIMOB INC (02013) plans to discount approximately 8.87% of the total issued shares of 6.88 billion subscription shares, raising approximately 1.55 billion HKD.

ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.

DL Holdings GP (01709): Purchased 2.152 million shares under the restricted stock incentive plan for the year 2025.
